Acute cardiovascular complications of disseminated intravascular coagulation in acute myeloid leukemia

Ghada Araji1, Ahmad Mustafa2, Muhammad Niazi3

  • 1Northwell Health/Staten Island University Hospital, Department of Internal Medicine, Staten Island, NY, USA.

Thrombosis Research
|May 26, 2024
PubMed

Insights

Disseminated intravascular coagulation (DIC) in Acute Myeloid Leukemia (AML) patients significantly increases risks for cardiovascular events like heart attack and heart failure. Close monitoring is crucial for these high-risk patients.

Area of Science:

  • Hematology
  • Cardiology
  • Oncology

Background:

  • Disseminated intravascular coagulation (DIC) is a known complication in leukemia, particularly Acute Myeloid Leukemia (AML).
  • The association between DIC and acute cardiovascular complications in AML has not been previously reported.

Purpose of the Study:

  • To investigate the link between DIC and acute cardiovascular complications in patients with Acute Myeloid Leukemia.
  • To analyze the impact of DIC on mortality and specific cardiovascular events in AML patients.

Main Methods:

  • Utilized the National Inpatient Sample Database for AML patient data.
  • Employed greedy propensity matching to create comparable cohorts with and without DIC.
  • Performed univariate and binary logistic regression analyses to assess outcomes.

Main Results:

  • Out of 37,344 AML patients, 996 had DIC.
  • DIC patients exhibited significantly higher rates of mortality, acute myocardial infarction, pulmonary edema, cardiac arrest, and DVT/PE.
  • Post-matching logistic regression confirmed increased acute heart failure rates in DIC patients.

Conclusions:

  • DIC in AML patients is associated with a substantial increase in acute cardiovascular complications and mortality.
  • Highlights the critical need for vigilant cardiovascular monitoring in AML patients with DIC.
  • Suggests further research into the mechanisms and targeted interventions for these complications.
Abstract

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
845
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.2K